Administration Instructions:

• Factor XIII is administered by intravenous injection, typically over 10–15 minutes.

   

• Reconstitution is required if using lyophilized powder; this is done by trained healthcare personnel or caregivers at home.

   

• Doses should be administered at regular monthly intervals to maintain effective FXIII levels.

   

Home Infusion Tips:

• Clean the infusion site with antiseptic before starting.

   

• Monitor for any signs of allergic reaction or infusion-related side effects.

   

• Maintain a treatment log for doses given and any symptoms observed.

   

Post-Treatment Care:

• Patients are usually advised to rest briefly after infusion.

   

• Routine blood tests may be scheduled to assess FXIII activity levels and guide further dosing.

   

Factor XIII plays a critical role in the final step of the blood coagulation cascade. While other clotting factors form a fibrin clot, FXIII is responsible for cross-linking fibrin strands, making the clot stable and durable. Without FXIII, clots are unstable and dissolve prematurely, resulting in recurrent or spontaneous bleeding.

Factor XIII replacement therapy works by:

• Replenishing deficient FXIII levels in the bloodstream.

   

• Enhancing fibrin stability in blood clots to prevent early breakdown.

   

• Preventing spontaneous bleeding in soft tissues, muscles, and joints.

   

• Improving wound healing by supporting clot maturation.

   

This mechanism is crucial for preventing both minor and major bleeding, especially in high-risk areas like the brain and internal organs.

Common Side Effects:

• Mild headache

   

• Injection site reactions (pain, redness, swelling)

   

• Low-grade fever

   

• Fatigue or malaise

   

These effects are typically short-lived and manageable without stopping treatment.

Serious Side Effects:

• Allergic reactions: Symptoms include rash, itching, swelling, dizziness, or difficulty breathing. Immediate medical attention is required.

   

• Antibody formation: Rare but possible—some patients may develop inhibitory antibodies that neutralize FXIII, reducing treatment effectiveness.

   

• Thrombotic events: Though rare, the risk of blood clots may increase, particularly in those with underlying risk factors or with overuse.

   

Always report any unusual symptoms or side effects to a healthcare provider promptly.

• Allergic Reactions: Monitor closely during and after infusions, especially in patients receiving the treatment for the first time.

   

• Inhibitor Development: Regular testing for neutralizing antibodies is advised in patients with suboptimal response.

   

• Pregnancy and Breastfeeding:

   

  • FXIII therapy is generally considered safe, but should be used during pregnancy only if clearly needed.

     

  • It is unknown whether FXIII passes into breast milk.

     

• Thromboembolism Risk: Use with caution in patients with a history of blood clots or conditions that predispose to thrombosis.

   

Pediatric Use: Approved for use in children with adjusted doses based on body weight and bleeding risk.

• Factor XIII has no known significant drug interactions, but caution should still be used when combining with:

   

  • Antifibrinolytic agents (e.g., tranexamic acid), which may increase clot stability excessively.

     

  • Other clotting factor concentrates—co-administration should be done only under medical guidance.

     

• Always disclose all medications, supplements, or herbal remedies being used to the prescribing physician.

   

• Maintenance Therapy: 35 IU/kg once every 4 weeks is standard for prophylaxis.

   

• Bleeding Episode: Dosage depends on FXIII activity levels, severity of the bleed, and clinical judgment.

   

Surgery or Trauma: Higher or more frequent doses may be needed to ensure hemostatic coverage.

Factor XIII is a prescription-only medication and must be prescribed and supervised by a hematologist or physician specializing in bleeding disorders. It is not available over the counter due to the complexity of the condition and the need for individualized dosing and monitoring.

• Diagnosis Confirmation: Requires laboratory confirmation of congenital FXIII deficiency.

   

• Insurance Authorization: Coverage often requires prior authorization due to the high cost and rare nature of the medication.

   

• Training and Support: Patients and caregivers often receive training for home infusion and management of minor reactions.

   

Manufacturer and patient assistance programs may be available to help with access and affordability.

• What is Factor XIII?
  Factor XIII (FXIII) is a blood-clotting protein (coagulation factor) essential for stabilizing blood clots.

• What is Factor XIII concentrate used for?
  It is used as a replacement therapy in patients with congenital or acquired Factor XIII deficiency to prevent or control bleeding.

• What products are available?

  • Corifact® (human plasma-derived Factor XIII concentrate)

  • Tretten® (recombinant Factor XIII-A subunit, rFXIII-A2)

• How does Factor XIII therapy work?
  It replaces the missing or deficient clotting factor, helping to form stable, long-lasting blood clots and prevent bleeding episodes.

• Who needs Factor XIII therapy?
  People with inherited FXIII deficiency, a rare bleeding disorder, or those with acquired deficiency (after severe trauma, surgery, or certain medical conditions).

• How is Factor XIII administered?
  Given as an intravenous (IV) infusion, usually once every 4 weeks for prophylaxis.

• Can Factor XIII be used to treat active bleeding?
  Yes, it can be used for both prevention and treatment of bleeding episodes.

• What are the common side effects?
  Headache, joint pain, injection-site reactions, mild fever, or fatigue.

• Are there serious side effects?
  Rare but possible—allergic reactions, blood clots (thrombosis), or anaphylaxis.

• Do patients need monitoring?
  Yes, Factor XIII activity levels should be monitored regularly to adjust dosing.

• Is Factor XIII safe for children?
  Yes, it is approved for use in pediatric patients with congenital FXIII deficiency.

• Is it safe during pregnancy?
  Can be used if needed—Factor XIII is essential for placenta stability and preventing miscarriage in deficient patients.

• Can it be used while breastfeeding?
  Yes, but always consult a doctor for monitoring.

• Does Factor XIII interact with other medicines?
  No major drug interactions, but caution is advised when combined with pro-coagulant drugs.

• How often is Factor XIII therapy needed?
  Typically every 4 weeks, though dosing may vary by patient response.

• What happens if a dose is missed?
  Patients should contact their healthcare provider—dosing should be resumed as soon as possible.

• Is Factor XIII deficiency common?
  No, it is a rare bleeding disorder (estimated incidence: 1 in 1–5 million people worldwide).

• Does Factor XIII therapy prevent surgery-related bleeding?
  Yes, prophylactic treatment helps reduce bleeding risk during surgery in FXIII-deficient patients.

• Are biosimilars or generics available?
  Currently, only branded Corifact® and Tretten® are widely available; no true generics exist yet.

• Where is Factor XIII therapy available?
  Through specialty pharmacies, hemophilia treatment centers, and hospitals.